Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07488117 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Study acronym: EAI-714
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Jun 2026 to Jun 2027 Recruitment opened · Start date changed from estimate of Mar 2026 to Mar 31, 2026 · Site details revisedv2 Show 3 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Mar 2026 to Mar 31, 2026
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.
Trial Details
NCT Number NCT07488117
Lead Sponsor University Hospital, Toulouse
Conditions Autoimmune Encephalitis (AE)
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov